← Leaderboards
Danni Li
University Of Minnesota
$6,299,696
Attributed
$7,280,476
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2018–25$5M$3.8M$2.5M$1.3M$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,280,476 · 5
By mechanism
R01$4,151,100 · 2
RF1$2,232,476 · 1
R21$896,900 · 2
Top collaborators
- Ling Li3 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Antoinette M Moran$24,819,193
- Eunice Oribamise$40,431
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposParticipantAffectImpaired CognitionS DiseaseNerve DegenerationBrainElderlyBiological MarkersBloodTreatment StrategyPlasmaS Disease RiskCognitionPreventPublic HealthPrevention StrategyStructureCostAcylcarnitineEnrollmentDementiaAmyloid DepositionCollection
Grant awards (13)
Impact of Mitochondrial Lipidomic Dynamics and its Interaction with APOE Isoforms on Brain Aging and Alzheimers Disease$638,436
R01 · FY2025 · AG
Impact of Mitochondrial Lipidomic Dynamics and its Interaction with APOE Isoforms on Brain Aging and Alzheimers Disease$658,484
R01 · FY2024 · AG
Identification of plasma lipoprotein proteins and lipids as biomarkers of innate-immunity and vascular contributions to Alzheimer's disease and Alzheimer's disease-related dementias in older adults$2,232,476
RF1 · FY2023 · AG · contact PI
Impact of Mitochondrial Lipidomic Dynamics and its Interaction with APOE Isoforms on Brain Aging and Alzheimers Disease$664,641
R01 · FY2023 · AG
Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and/or Cognitive Training in Amnestic Mild Cognitive Impairment$235,673
R01 · FY2022 · AG · contact PI
Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and/or Cognitive Training in Amnestic Mild Cognitive Impairment$480,197
R01 · FY2021 · AG · contact PI
Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and/or Cognitive Training in Amnestic Mild Cognitive Impairment$486,805
R01 · FY2020 · AG · contact PI
Identification of proteins in plasma lipoproteins as biomarkers to aid in diagnosing and predicting progression of Alzheimer's disease in older adults$201,509
R21 · FY2020 · AG · contact PI
Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and/or Cognitive Training in Amnestic Mild Cognitive Impairment$496,114
R01 · FY2019 · AG · contact PI
Identification of proteins in plasma lipoproteins as biomarkers to aid in diagnosing and predicting progression of Alzheimer's disease in older adults$246,563
R21 · FY2019 · AG · contact PI
Identification of plasma hydroxysphingolipids as biomarkers of demyelination and neurodegeneration underlying physical function decline in older adults$198,334
R21 · FY2019 · AG · contact PI
Blood Biomarkers as Surrogate Endpoints of Treatment Responses to Aerobic Exercise and/or Cognitive Training in Amnestic Mild Cognitive Impairment$490,750
R01 · FY2018 · AG · contact PI
Identification of plasma hydroxysphingolipids as biomarkers of demyelination and neurodegeneration underlying physical function decline in older adults$250,494
R21 · FY2018 · AG · contact PI